Lennart Vanglabeke, Marie Van den Bosch, Kenny Anseele, Tom Verbelen, Bart Meuris
{"title":"Alpha-Amino Oleic Acid as Anticalcification Agent for Porcine Bioprosthetic Heart Valves: A Narrative Review.","authors":"Lennart Vanglabeke, Marie Van den Bosch, Kenny Anseele, Tom Verbelen, Bart Meuris","doi":"10.1093/icvts/ivag246","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Calcification remains the principal mechanism limiting the durability of bioprosthetic heart valves. Alpha-amino oleic acid (AOA) was developed as an anticalcification treatment to preserve tissue integrity. This review synthesizes preclinical and clinical evidence on the efficacy of AOA-treated bioprosthetic valves.</p><p><strong>Methods: </strong>A narrative review was conducted using major biomedical databases to assess experimental and clinical studies evaluating AOA-treated tissues and valve platforms. Evidence from in vitro experiments, small/large animal models, and long-term clinical cohorts was qualitatively synthesized, with emphasis on calcification, structural valve degeneration, and durability outcomes.</p><p><strong>Results: </strong>Preclinical studies consistently demonstrated significant reductions in leaflet calcification in AOA-treated tissues compared with glutaraldehyde-fixed controls, across multiple models. These effects were most pronounced in leaflet tissue, whereas protection of the aortic wall or conduit tissue was less consistent. Large-animal models confirmed delayed mineralization and preservation of leaflet flexibility, but revealed susceptibility of non-leaflet components to calcific degeneration. Clinically, long-term follow-up of several surgical valve platforms incorporating AOA showed acceptable freedom from structural valve degeneration extending beyond ten years in selected patient populations. Durability remains strongly age-dependent, and late valve failures can still be associated with progressive calcification. Evidence from newer valve platforms is becoming available through various long-term follow-up studies.</p><p><strong>Conclusion: </strong>AOA provides effective anticalcification protection of bioprosthetic valve leaflets, supporting durable clinical performance in surgical platforms.</p>","PeriodicalId":73406,"journal":{"name":"Interdisciplinary cardiovascular and thoracic surgery","volume":" ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Interdisciplinary cardiovascular and thoracic surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/icvts/ivag246","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"0","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Calcification remains the principal mechanism limiting the durability of bioprosthetic heart valves. Alpha-amino oleic acid (AOA) was developed as an anticalcification treatment to preserve tissue integrity. This review synthesizes preclinical and clinical evidence on the efficacy of AOA-treated bioprosthetic valves.
Methods: A narrative review was conducted using major biomedical databases to assess experimental and clinical studies evaluating AOA-treated tissues and valve platforms. Evidence from in vitro experiments, small/large animal models, and long-term clinical cohorts was qualitatively synthesized, with emphasis on calcification, structural valve degeneration, and durability outcomes.
Results: Preclinical studies consistently demonstrated significant reductions in leaflet calcification in AOA-treated tissues compared with glutaraldehyde-fixed controls, across multiple models. These effects were most pronounced in leaflet tissue, whereas protection of the aortic wall or conduit tissue was less consistent. Large-animal models confirmed delayed mineralization and preservation of leaflet flexibility, but revealed susceptibility of non-leaflet components to calcific degeneration. Clinically, long-term follow-up of several surgical valve platforms incorporating AOA showed acceptable freedom from structural valve degeneration extending beyond ten years in selected patient populations. Durability remains strongly age-dependent, and late valve failures can still be associated with progressive calcification. Evidence from newer valve platforms is becoming available through various long-term follow-up studies.
Conclusion: AOA provides effective anticalcification protection of bioprosthetic valve leaflets, supporting durable clinical performance in surgical platforms.